We are a unique association of experts in the field of science, pharmaceuticals industry, biotechnology and financial engineering
About Us
We have found the ideal formula for investment productivity in one of the most complex application areas, which combines the advanced scientific achievements in the field of medicine, professional skills, successful experience and in-house funds.
Our mission is to make the best world medical practices and scientific developments a working tool for Russian doctors delivering medical care for patients suffering from severe, rare or incurable diseases.
Our main goals are the health of the nation, the development of domestic medicine and the financial well-being of investors.
5 principles:
Uniqueness
Reliability
Self-sustainability
Self-sufficiency
Efficiency
1/
3/
2/
4/
5/
The main feature of each project — novelty and exclusivity. We bring progress and high medical technologies just to those areas where there is a high need for them and guaranteed demand.
Our investment portfolio consists of projects in the success of which we are 100% sure. Participation in the project of institutional investors represented by the state and industry departments serves as additional guarantees for obtaining results.
The team of each project of the Fund brings together experts and highly professional industry experts whose competencies and experience allow them to evaluate tasks at 360° and make only the right decisions.
Each project of the Fund includes the obligatory elements of real production. This approach eliminates the negative impact of external factors, creates additional opportunities for profit and contributes to the development of domestic production and the medical technology industry.
We create mechanisms for effective care available to each patient. If scientists have found an opportunity to improve the patient's quality of life and stop the destructive impact of the disease, regardless of the stage and depth of the damage lesion, we will take on this project.
New Project Developments
Neutron capture therapy
Universal radioisotope carrier
Sol-gel Y-90 microspheres for radioembolization
Gadolinium NCT
Basic principle
Boron NCT
Neutron source for NCT
Gadolinium neutron capture is associated with production of gammas (energy range from 0,15 to 7 MeV). As well as short range Auger and IC electrons.
Boron neutron capture is associated with production of high LET radiation (He and Li ions), that has very short range, equal to the dimensions of chromosome (less then 10 micrometers).
There are two ways to produce neutron beams with required parameters (fluence, energy), suitable for NCT.
Development of a radiopharmaceutical drug based on samarium-153 and bio-degradable capsules for radioembolization of liver neoplasms
Development of a radiopharmaceutical drug based on encapsulated radium-223/radium-224 for intracavitary radiation therapy (treatment of peritoneal carcinomatosis (for stomach, colon, ovarian cancer) and pleura (for lung and breast cancer)
Development of a radiopharmaceutical drug based on a fibroblast activating factor inhibitor (FAPI) with improved pharmacokinetics for theranostics (PET-CT diagnostics and systemic radiation therapy):
Development includes: creation of an active drug substance, selection of the optimal composition of excipients, creation of a finished dosage form, automation of synthesis based on original (including cassette) synthesis modules, development of a drug specification, quality control methods and their validation, quality standard, preclinical studies of the efficacy and safety of drugs
Development includes: creation of an active drug substance, selection of the optimal composition of excipients, creation of a finished dosage form, automation of synthesis based on original (including cassette) synthesis modules, development of a drug specification, quality control methods and their validation, quality standard, preclinical studies of the efficacy and safety of drugs
Clinical studies of a radiopharmaceutical drug based on nanoantibodies to GITR and CTLA-4 receptors labeled with lutetium-177 for the treatment of generalized forms of kidney and bladder cancer (phase III studies). The same radiopharmaceutical drug labeled with 68Ga is offered as a diagnostic preparation (for PET-CT).
Method for automated synthesis of radiopharmaceuticals based on polymeric microparticles using a device for its implementation. Platform solution for application of radioisotopes.
Тheranostics and radiopharmaceutical drugs
Technologies
Everyone — doctors, scientists, investors, the richest people on the planet and the strongest of this world understand the imperfection and vulnerability of a human being to diseases and old age. Investment amounts in modern pharmaceuticals, medical developments and biotechnologies break records every year.
In the last three years alone, cash flow to advanced research and pharmaceuticals has increased by more than 3 times.
In the last three years alone, cash flow to advanced research and pharmaceuticals has increased by more than 3 times.
No. We are convinced realists and practitioners. Therefore, most of our projects are designed to solve the problems of real patients who need immediate help. At the same time, we carefully select ideas in order to gradually introduce the technologies of the future of medicine.
Here are a few areas that we consider promising:
Here are a few areas that we consider promising:
Human being is the weakest and most imperfect link in the rapidly changing world of digital and technological progress. This is an obvious and scientifically recognized fact.
Do we believe in biohacking, theories of technological singularity and anti-aging movement?
Platform technologies
Theranostics
Minimally invasive surgery
Personalized immunotherapy
Telemedicine
Genomic biotechnologies
Bioprosthetic and 3D printing
Team
Our longstanding relationships and strong ties with leading medical communities and research institutions help make the Fund an attractive investment partner. Differentiated capital allows us to provide solutions for a wide range and develop individual investment projects based on strategic values.
The Fund is managed by a team of experienced professionals
We use reliable investment solutions that combine income from various sources in the public and private markets.
FAQ
What is the shortest investment time frame?
What's the price of the “entry” and what is the average return?
How to become a co-investor?
We do not support the myths that investment in pharmaceuticals and biotech is a long history with unpredictable results. The minimum payback period for our projects is 5-6 years. The maximum investment time frame is 10 years.
Like any high-tech area, projects in the field of pharmaceuticals and medical production are referred to capital-intensive investments. The starting capital for launching the Fund's project starts from 2 million USD with a high IRR.
The worldwide high demand of investors for high-tech projects in the field of pharmaceuticals and biotech has made this area one of the most profitable. Complete our questionnaire and find the project that suits you — write to us at info@nvtech.pro
Leave your feedback
Feedback
info@nvtech.pro
Russia · UAE · China · Central Asia
E-mail
Focus markets
I agree with the Privacy Policy by clicking on the “Submit” button
© NV Tech, 2026
Russia · UAE · China · Central Asia
Focus markets
E-mail
Navigation